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Abstract
Background: Clinical trial results’ reliability is impacted by reporting bias. This is primarily manifested as publication
bias and outcome reporting bias.
Mental health trials’ specific features: Mental health trials are prone to two methodological deficiencies: (1) using
small numbers of participants that facilitates false positive findings and exaggerated size effects, and (2) the obligatory
use of psychometric scales that require subjective assessments. These two deficiencies contribute to the publication of
unreliable results. Considerable reporting bias has been found in safety and efficacy findings in psychotherapy and
pharmacotherapy trials. Reporting bias can be carried forward to meta-analyses, a key source for clinical practice
guidelines. The final result is the frequent overestimation of treatment effects that could impact patients and clinician-
informed decisions.
Mechanisms to prevent outcome reporting bias: Prospective registration of trials and publication of results are the
two major methods to reduce reporting bias. Prospective trial registration will allow checking whether they are published
(so it will help to prevent publication bias) and, if published, whether those outcomes and analyses that were deemed as
appropriate before trial commencement are actually published (hence helping to find out selective reporting of
outcomes). Unfortunately, the rate of registered trials in mental health interventions is low and, frequently, of
poor quality.
Conclusion: Clinicians should be prudent when interpreting the results of published trials and some meta-analyses –
such as those conducted by scientists working for the sponsor company or those that only include published trials.
Prescribers, however, should be confident when prescribing drugs following the summary of product characteristics,
since regulatory agencies have access to all clinical trial results.
Keywords: Clinical trials, Meta-analysis, Psychotherapy, Pharmacotherapy, Publication bias, Outcome reporting bias
Background
It is well known that the reliability of published clinical
trial results is far from optimal [1, 2]. Reporting bias is a
structural problem present in both publicly funded and
privately sponsored trials. It is primarily manifested as
publication bias (many trials are not published at all,
mainly because they did not yield positive results) and
outcome reporting bias or selective outcome reporting
(only outcomes or analyses yielding positive results are
published). Both types of bias typically result in an over-
estimation of the benefits and an underestimation of the
risks. This could easily lead to erroneous therapeutic de-
cisions by clinicians and patients.
What it is not so well known is that the two disciplines
dealing with mental health, psychology and psychiatry,
are at the very top of the ranking of all natural and social
sciences with regards to publication bias: 91.5% of all ar-
ticles publish positive results [3]. This finding was
already described more than 50 years ago when Sterling
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[4] showed that 97% of all published studies on psych-
ology rejected the null hypothesis. More recently, an un-
usually high prevalence of psychology studies published
with a p value of just below 0.05 has been observed: the
number of studies with a p value of between 0.045 and
0.05 is much higher than that expected [5]. Furthermore,
in 9% of psychology trials reported p values are incon-
sistent with the reported statistic [6].
Clinical trials on mental health interventions and
reporting bias
Clinical trials assessing mental health interventions are
prone to two major methodological deficiencies that, ul-
timately, contribute to the publication of unreliable re-
sults. The first deficiency relates to the low number of
trial participants: the low statistical power associated with
small numbers of participants facilitates the finding of
false positive results and exaggerated size effects [7, 8].
A search conducted on ClinicalTrials.gov [9] on 9
December 2015 on clinical trials on psychotherapy,
showed that 909 trials were registered and that the me-
dian number of participants among 91 trials randomly
chosen from those 909 was 120; however, the median
number of patients on 43 pivotal trials on drugs for
psychiatric conditions approved between 2005 and
2012 in the US was 432 [10], i.e., 3.6 times higher. In
addition to that, a recent study found that more than
50% of 100 psychology trials could not be replicated;
furthermore, the mean effect size among replicated
studies was half of that described in the original articles
[11]. Of note is that a low number of trial participants
could also yield to false negative results that, if pub-
lished, could mislead clinicians.
The second deficiency refers to the use of outcomes
requiring a certain grade of interpretation, such as
psychometric scales: since these require a subjective
assessment, they are prone to remarkable variability
depending on the implemented analytical option [7, 8]. In
these cases, in a trial with a small sample size, the magni-
tude of the estimated effect could vary (the so-called ‘vi-
bration effect’) and will depend on factors such as the
principal endpoint (psychometric scale) chosen, the use of
adjustments for certain confounders and the availability of
alternative options in statistical approach [12].
Publication bias is common on mental health trials.
Thus, in clinical trials on treatments of psychiatric
conditions considerable publication bias has been
found. In major depression a reduction of 25–29% of
the effect size of psychotherapy was observed when
adding the results of unpublished trials to those to
published trials [13, 14]. Publication bias and selective
outcome reporting have been also described for drug
trials for major depression [15], anxiety disorders [16]
and schizophrenia [17] in which sponsor companies
decided to mainly publish positive trials, outcomes
and analyses.
Safety information is rarely reported in both drug and
psychological intervention trials. Outcome reporting bias
of key safety results is common in trials on antidepres-
sants and antipsychotics: when comparing the data in-
cluded in the corresponding clinical trial registries, only
57%, 38%, and 47% of serious adverse events, cases of
deaths or suicide were reported in articles, respectively
[18]. In psychotherapy the picture is remarkably worse
since harms of the interventions are rarely reported: pos-
sible or actual adverse reporting is 9 to 20 times more
likely in pharmacotherapy trials than in psychotherapy
trials [19]. All these biases have a considerable impact
on the benefit and risks reported for mental health
interventions.
Network meta-analyses on mental health inter-
vention trials and reporting bias
The relevance of reporting bias is much greater if these
are carried forward to meta-analyses, a key source for
clinical practice guidelines. In disorders having a number
of commercially available drugs, but with few head-to-
head comparative trials, it is common to conduct net-
work meta-analysis. In these, investigators aim to rank
all medicines after conducting direct and, mostly, indir-
ect comparisons between available drugs. In a network
meta-analysis with trials of antidepressants versus pla-
cebo, publication bias modified the ranking order of the
first three drugs if unpublished trials were taking into
account [20]. This was not the case in a network meta-
analysis with antipsychotics, most likely due to the use
of head-to-head comparative trials and the fact that pub-
lication bias in antipsychotic trials is less common than
with antidepressants [21].
How to prevent reporting bias
There are two major methods to reduce trial results’
reporting bias. One is to prospectively register the trial
or systematic review or meta-analysis in a public registry
before the start of the trial or review. Trials could be
registered in a number of registries that accept both tri-
als on medicines and psychotherapy such as, for in-
stance, ClinicalTrials.gov [9] or ISRCTN [22], whereas
systematic reviews could be registered on International
Prospective Register of Systematic Reviews (PROSPERO)
[23]. The other method is to publish all the results ob-
tained. Both are described in the Consolidated Standards
of Reporting Trials (CONSORT) Statement [24] for tri-
als and the Preferred Reporting Items for Systematic Re-
views and Meta-Analyses (PRISMA) guidelines [25] for
meta-analyses. However, these guidelines for reporting
outcomes are rarely required by psychiatry journals [26].
Prospective trial registration will allow checking whether
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they are published (so it will help to prevent publication
bias) and, if published, whether those outcomes and ana-
lyses that were deemed as appropriate before trial com-
mencement are actually published (hence helping to find
out selective reporting of outcomes). These two require-
ments are mandatory for medicine trials in the European
Union and the US; this, however, is not the case for non-
regulated interventions, such as psychotherapy [27]. How-
ever, this has changed but only for psychotherapy US
National Institutes of Health-funded trials: in January
2017 a new policy on trial registration and publication of
results has come into force [28], so psychotherapy trials
will have to be registered and their results published. From
an ethical perspective, the Declaration of Helsinki has also
asked for these two requirements since 2008 [29].
Unfortunately, the rate of registered trials is low – only
25% of psychiatry journals ask for preregistration of tri-
als to have the results published [26] – and, in many
cases, of poor quality. Thus, among the top five psych-
iatry journals, that also ask for preregistration of trials,
only 33% of 181 trials published in 2009–2013 were reg-
istered before the onset of participant enrollment,
whereas only 14% had, in addition, no outcome report-
ing bias [30]. In other analysis, among 170 trials on de-
pression published between 2011 and 2013, only 33%
and 20% of trials assessing drugs and cognitive behavior
therapy were appropriately registered (i.e., before study
start and reporting fully specified outcomes), respectively
[31]. With regards to psychotherapy, a recent systematic
review on 112 randomized clinical trials published be-
tween 2010 and 2014, showed that only 18% were pro-
spectively registered and only 5% were free of outcome
reporting bias [32].
Reporting bias and clinical practice
Prescribers should interpret the results of clinical tri-
als and meta-analyses with caution: publication in a
prestigious journal does not prevent selective report-
ing of outcomes. It would seem reasonable to expect
that journal editors should implement rigorous quality
control mechanisms to prevent outcome reporting
bias [33]. Because that is not implemented yet, clini-
cians should have a certain degree of skepticism with
regards to all clinical trial results, irrespective of the
types of intervention assessed. Clinicians cannot be
expected to compare the information included in an
article with that provided on the trial registry. On the
other hand, although there are a number of methods
to explore whether a meta-analysis presents any type
of bias [34], they are not feasible for the vast majority
of clinicians. Prescribers should be especially skeptical
when reading the results of meta-analyses when (1)
scientists of the sponsor company were involved [35],
and (2) no unpublished trials are included, since this
usually implies a variable impact on the direction and
size of the therapeutic effect [36].
It should be highlighted, however, that since regula-
tory agencies have access to the results of all clinical
trials with medicines, the clinician should be confident
when filling a prescription following the authorized
summary of product characteristics. The situation is
very different with trials on off-label indications, where
selective outcome reporting is common [37], and with
trials conducted not to amend the approved indication,
posology or target population of a drug, but to inform
prescription habits (e.g., comparative effectiveness tri-
als) that are not subject to regulatory agency in-depth
review: articles of these two types of trial are subject
only to the peer-review process which has no impact in
rejecting for publication manuscripts with discrepancies
in registries [38]. Clinicians should be even more
skeptical when reading psychotherapy trials that, since
they are not regulated, could easily present outcome
reporting bias of both benefits and harms, hence hin-
dering the benefit/risk assessment.
Concluding remarks
The only way to ensure the absence (or minimization) of
outcome reporting bias is by implementing better-
quality control procedures during the editorial process,
such as a thorough cross-checking between the manu-
script and the protocol or registry [39]. Until this hap-
pens, clinicians should be prudent when interpreting the
results of published trials and some systematic reviews/
meta-analyses. This is based on the fairly frequent pres-
ence of outcome reporting bias that tends to overesti-
mate treatment effects in mental health trials. As a
nonregulated intervention, psychotherapy trials are espe-
cially prone to this fact. Pharmacotherapy is also subject
to outcome reporting bias, but since regulatory agencies
will have access to pivotal trials results, the summary of
product characteristics is a fair description on how a
drug can be correctly prescribed.
Acknowledgements
We thank Dr. Eric Turner (Departments of Psychiatry and Pharmacology,
Oregon Health and Science University, Portland, OR, USA) for helpful
comments on a previous version of this paper.
Funding
This work required no funding.
Availability of data and materials
NA
Authors’ contributions
RD-R conceived the idea and wrote the first draft of the manuscript. JB and
PC made substantial revisions for intellectual content. All authors approved
the final version of the manuscript and are accountable for all aspects
included in it.
Competing interests
The authors declare that they have no competing interests.
Dal-Ré et al. Trials  (2017) 18:143 Page 3 of 4
Consent for publication
NA
Ethics approval and consent to participate
NA
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Clinical Research, BUC (Biosciences UAM+CSIC) Program, International
Campus of Excellence, Universidad Autónoma de Madrid, Ciudad
Universitaria de Cantoblanco, c/Einstein 3, 28049 Madrid, Spain. 2Department
of Psychiatry, School of Medicine, University of Oviedo, C/ San Francisco, 1,
33003 Oviedo, Asturias, Spain. 3CIBERSAM, Madrid, Spain. 4Department of
Clinical, Neuro and Developmental Psychology, Vrije Universiteit Amsterdam,
De Boelelaan 1105, 1081 HV Amsterdam, The Netherlands. 5EMGO Institute
for Health and Care Research, Amsterdam, The Netherlands.
Received: 26 October 2016 Accepted: 13 March 2017
References
1. Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al. The
impact of outcome reporting bias in randomised controlled trials on a
cohort of systematic reviews. BMJ. 2010;340:c365.
2. Saini P, Loke YK, Gamble C, Altman DG, Williamson PR, Kirkham JJ. Selective
reporting bias of harm outcomes within studies: findings from a cohort of
systematic reviews. BMJ. 2014;349:g6501.
3. Fanelli D. “Positive” results increase down the hierarchy of the sciences.
PLoS One. 2010;5:e10068.
4. Sterling T. Publication decisions and their possible effects on inferences drawn
from tests of significance, or vice versa. J Am Stat Assoc. 1959;285:30–4.
5. Masicampo EJ, Lalande DR. A peculiar prevalence of p values just below.05.
Q J Exp Psychol (Hove). 2012;65:2271–9.
6. Krawczyk M. The search for significance: a few peculiarities in the
distribution of P values in experimental psychology literature. PLoS One.
2015;10:e0127872.
7. Ioannidis JP. Why most published research findings are false. PLoS Med.
2005;2:e124.
8. Button KS, Ioannidis JP, Mokrysz C, Nosek BA, Flint J, Robinson ES, et al.
Power failure: why small sample size undermines the reliability of
neuroscience. Nat Rev Neurosci. 2013;14:365–76.
9. US National Institutes of Health. ClinicalTrials.gov https://clinicaltrials.gov/.
Accessed 15 Feb 2017.
10. Downing NS, Aminawung JA, Shah ND, Krumholz HM, Ross JS. Clinical trial
evidence supporting FDA approval of novel therapeutic agents, 2005-2012.
JAMA. 2014;311:368–77.
11. Open Science Collaboration. Estimating the reproducibility of psychological
sciences. Science. 2015;349(943):aac4716.
12. Ioannidis JPA. Why most discovered true associations are inflated.
Epidemiology. 2008;19:640–8.
13. Cuijpers P, Smit F, Bohlmeijer E, Hollon SD, Andersson G. Efficacy of cognitive-
behavioural therapy and other psychological treatments for adult depression:
meta-analytic study of publication bias. Br J Psychiatry. 2010;196:173–8.
14. Driessen E, Hollon SD, Bockting CL, Cuijpers P, Turner EH. Does publication
bias inflate the apparent efficacy of psychological treatment for major
depressive disorder? A systematic review and meta-analysis of US National
Institutes of Health-Funded Trials. PLoS One. 2015;10:e0137864.
15. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective
publication of antidepressant trials and its influence on apparent efficacy. N
Engl J Med. 2008;358:252–60.
16. Roest AM, de Jonge P, Williams CD, de Vries YA, Schoevers RA, Turner EH.
Reporting bias in clinical trials investigating the efficacy of second-
generation antidepressants in the treatment of anxiety disorders: a report of
2 meta-analyses. JAMA Psychiat. 2015;72:500–10.
17. Turner EH, Knoepflmacher D, Shapley L. Publication bias in antipsychotic
trials: an analysis of efficacy comparing the published literature to the US
Food and Drug Administration Database. PLoS Med. 2012;9:e1001189.
18. Hughes S, Cohen D, Jaggi R. Differences in reporting serious adverse events
in industry sponsored clinical trial registries and journal articles on
antidepressant and antipsychotic drugs: a cross sectional study. BMJ Open.
2014;4:e005535.
19. Vaughan B, Goldstein MH, Alikakos M, Cohen LJ, Serby MJ. Frequency of
reporting of adverse events in randomized controlled trials of psychotherapy
vs. psychopharmacotherapy. Compr Psychiatry. 2014;55:849–55.
20. Trinquart L, Abbe A, Ravaud P. Impact of reporting bias in network meta-
analysis of antidepressant placebo-controlled trials. PLoS One. 2012;7:e35219.
21. Mavridis D, Efthimiou O, Leucht S, Salanti G. Publication bias and small-study
effects magnified effectiveness of antipsychotics but their relative ranking
remained invariant. J Clin Epidemiol. 2015;69:161–9.
22. BioMed central. ISRCTN registry. http://www.isrctn.com/. Accessed 15 Feb 2017.
23. UK National Institute for Health Research. PROSPERO. International
prospective register of systematic reviews. https://www.crd.york.ac.uk/
PROSPERO/. Accessed 15 Feb 2017.
24. CONSORT Transparent reporting of trials. CONSORT Statement. http://www.
consort-statement.org/. Accessed 15 Feb 2017.
25. EQUATOR Network. Enhancing the QUAlity and Transparency Of health
Research. http://www.equator-network.org/reporting-guidelines/prisma/.
Accessed 15 Feb 2017.
26. Knuppel H, Metz C, Meerpohl JJ, Strech D. How psychiatry journals support
the unbiased translation of clinical research. A cross-sectional study of
editorial policies. PLoS One. 2013;8:e75995.
27. Dal-Ré R, Bracken MB, Ioannidis JP. Call to improve transparency of trials of
non-regulated interventions. BMJ. 2015;350:h1323.
28. National Institutes of Health. NIH Policy on the Dissemination of NIH-Funded
Clinical Trial Information. Notice Number: NOT-OD-16-149. Release date: 16
September 2016. http://grants.nih.gov/grants/guide/notice-files/NOT-OD-16-
149.html. Accessed 15 Feb 2017.
29. World Medical Association. The Declaration of Helsinki. http://www.wma.
net/es/30publications/10policies/b3/17c.pdf. Accessed 15 Feb 2017.
30. Scott A, Rucklidge JJ, Mulder RT. Is mandatory prospective trial registration
working to prevent publication of unregistered trials and selective outcome
reporting? An observational study of five psychiatry journals that mandate
prospective clinical trial registration. PLoS One. 2015;10:e0133718.
31. Shinohara K, Tajika A, Imai H, Takeshima N, Hayasaka Y, Furukawa TA.
Protocol registration and selective outcome reporting in recent psychiatry
trials: new antidepressants and cognitive behavioral therapies. Acta
Psychiatr Scand. 2015;132:489–98.
32. Bradley HA, Rucklidge JJ, Mulder RT. A systematic review of trial registration
and selective outcome reporting in psychotherapy randomized controlled
trials. Acta Psychiatr Scand. 2017;135:66–75.
33. Dal-Ré R, Caplan AL. Journal editors’ impasse with outcome reporting bias.
Eur J Clin Invest. 2015;45:895–8.
34. Mavridis D, Salanti G. How to assess publication bias: funnel plot, trim-and-fill
method and selection models. Evid Based Ment Health. 2014;17:30.
35. Ebrahim S, Bance S, Athale A, Malachowski C, Ioannidis JP. Meta-analyses
with industry involvement are massively published and report no caveats
for antidepressants. J Clin Epidemiol. 2016;70:155–63.
36. Hart B, Lundh A, Bero L. Effect of reporting bias on meta-analyses of drug
trials: reanalysis of meta-analyses. BMJ. 2012;344:d7202.
37. Vedula SS, Li T, Dickersin K. Differences in reporting of analyses in internal
company documents versus published trial reports: comparisons in industry-
sponsored trials in off-label uses of gabapentin. PLoS Med. 2013;10:e1001378.
38. van Lent M, IntHout J, Out HJ. Differences between information in registries
and articles did not influence publication acceptance. J Clin Epidemiol.
2015;68:1059–67.
39. Ioannidis J, Caplan AL, Dal-Ré R. Outcome reporting bias in clinical trials:
why monitoring matters. BMJ. 2017;356:j408.
Dal-Ré et al. Trials  (2017) 18:143 Page 4 of 4
